News

Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV. The

The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has

The QIDP status provides for accelerated review of the New Drug Application (NDA) as well as a five-year period of market exclusivity for the indication, if approved. Currently,

According to information published on clinicaltrials.gov, the randomized, subject- and investigator-blinded study will enroll 60 obese adult patients with type 2 diabetes to assess the safety, pharmacokinetics and

The US Court of Appeals for the Federal Circuit has upheld the earlier district court's decision that a proposed generic equivalent from Teva Pharmaceutical Industries would infringe on

Merck paid $230m upfront for two clinical-stage DNA damage and repair candidates and two additional preclinical programs, of which the company will take full responsibility in development and commercialization. US-based

This global Phase 2a clinical trial is being conducted in approximately 150 ambulatory patients diagnosed with influenza A. Patients in the Phase 2a clinical trial will be randomized

The marketing authorization allows for the marketing of TAF in the 28 countries of the European Union, Norway and Iceland. University of Milan Fondazione IRCCS Ca’ Granda Ospedale

Orphan drug designations are granted to drugs and biologics intended to treat rare diseases. The designation provides incentives to advance development of rare disease drugs and for commercialization